IRIX

Company Overview — What Does IRIDEX CORP Do?

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. IRIDEX CORP (IRIX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO David I. Bruce and employs approximately 120 people, headquartered in MOUNTAIN VIEW, California. With a market capitalization of $16M, IRIX is one of the notable companies in the Healthcare sector.

IRIDEX CORP (IRIX) Stock Rating — Reduce (April 2026)

As of April 2026, IRIDEX CORP receives a Reduce rating with a composite score of 32.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IRIX ranks #3,534 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, IRIDEX CORP ranks #556 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IRIX Stock Price and 52-Week Range

IRIDEX CORP (IRIX) currently trades at $0.98. The stock lost $0.06 (5.8%) in the most recent trading session. The 52-week high for IRIX is $1.65, which means the stock is currently trading -40.5% from its annual peak. The 52-week low is $0.79, putting the stock 24.1% above its annual trough. Recent trading volume was 229K shares, suggesting relatively thin trading activity.

Is IRIX Overvalued or Undervalued? — Valuation Analysis

IRIDEX CORP (IRIX) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.62x, versus the sector average of 2.75x. The price-to-sales ratio is 0.34x, compared to 1.66x for the average Healthcare stock.

At current multiples, IRIDEX CORP trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

IRIDEX CORP Profitability — ROE, Margins, and Quality Score

IRIDEX CORP (IRIX) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -104.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -17.6% versus the sector average of -33.1%.

On a margin basis, IRIDEX CORP reports gross margins of 33.3%, compared to 71.5% for the sector. The operating margin is -9.1% (sector: -66.1%). Net profit margin stands at -10.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 4.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IRIX Debt, Balance Sheet, and Financial Health

IRIDEX CORP has a debt-to-equity ratio of 492.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.91x, suggesting adequate working capital coverage. Total debt on the balance sheet is $4M. Cash and equivalents stand at $6M.

IRIX has a beta of 0.92, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for IRIDEX CORP is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

IRIDEX CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, IRIDEX CORP reported revenue of $52M. Net income for the quarter was $-5M. Gross margin was 33.3%. Operating income came in at $-5M.

In FY 2026, IRIDEX CORP reported revenue of N/A.

In Q3 2026, IRIDEX CORP reported revenue of $12M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-2M. Gross margin was 32.1%. Revenue grew 0.0% year-over-year compared to Q3 2025. Operating income came in at $-1M.

In Q3 2025, IRIDEX CORP reported revenue of $12M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-2M. Gross margin was 32.1%. Operating income came in at $-1M.

Over the past 8 quarters, IRIDEX CORP has demonstrated a growth trajectory, with revenue expanding from $12M to $52M. Investors analyzing IRIX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IRIX Dividend Yield and Income Analysis

IRIDEX CORP (IRIX) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IRIX Momentum and Technical Analysis Profile

IRIDEX CORP (IRIX) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 31/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

IRIX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, IRIDEX CORP (IRIX) ranks #556 out of 838 stocks based on the Blank Capital composite score. This places IRIX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IRIX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IRIX vs S&P 500 (SPY) comparison to assess how IRIDEX CORP stacks up against the broader market across all factor dimensions.

IRIX Next Earnings Date

No upcoming earnings date has been announced for IRIDEX CORP (IRIX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IRIX? — Investment Thesis Summary

The quantitative profile for IRIDEX CORP suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. High volatility (stability score 33/100) increases portfolio risk.

In summary, IRIDEX CORP (IRIX) earns a Reduce rating with a composite score of 32.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IRIX stock.

Related Resources for IRIX Investors

Explore more research and tools: IRIX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IRIX head-to-head with peers: IRIX vs AZN, IRIX vs SLGL, IRIX vs VMD.